Edition:
United States

Cepheid (CPHD.OQ)

CPHD.OQ on NASDAQ Stock Exchange Global Select Market

52.63USD
4:00pm EDT
Change (% chg)

-- (+0.00%)
Prev Close
$52.63
Open
$52.62
Day's High
$52.70
Day's Low
$52.56
Volume
574,003
Avg. Vol
347,270
52-wk High
$52.86
52-wk Low
$25.09

CPHD.OQ

Chart for CPHD.OQ

About

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The... (more)

Overall

Beta: 0.41
Market Cap(Mil.): $3,842.37
Shares Outstanding(Mil.): 73.01
Dividend: --
Yield (%): --

Financials

  CPHD.OQ Industry Sector
P/E (TTM): -- 45.07 36.20
EPS (TTM): -0.68 -- --
ROI: -7.21 7.62 13.87
ROE: -13.17 9.71 14.78

BRIEF-S&P places Danaher Corp. 'A' ratings on watch negative on planned acqusition of Cepheid

* S&P - Danaher Corp. 'A' ratings placed on watch negative on planned acqusition of Cepheid

Sep 06 2016

Danaher to buy Cepheid in $4 billion deal to expand in diagnostics

Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

Sep 06 2016

UPDATE 3-Danaher to buy Cepheid in $4 bln deal to expand in diagnostics

Sept 6 Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

Sep 06 2016

BRIEF-Moody's says Danaher's A2 rating unaffected by planned acquisition of Cepheid

* Moody's: Danaher's A2 rating unaffected by planned acquisition of Cepheid for $4 billion Source text for Eikon: Further company coverage:,

Sep 06 2016

BRIEF-Danaher to acquire Cepheid for $53.00 per share, or about $4 billion

* Danaher to acquire Cepheid for $53.00 per share, or approximately $4 billion

Sep 06 2016

Danaher to buy Cepheid for about $4 bln, including debt

Sept 6 Danaher Corp said it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt.

Sep 06 2016

BRIEF-Cepheid Q1 loss per share $0.09

* Q1 earnings per share view $0.01 -- Thomson Reuters I/B/E/S

Apr 28 2016

BRIEF-Cepheid announces partner distribution agreement with Medline

* Cepheid announces partner distribution agreement with medline

Apr 21 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.